Featured Research

from universities, journals, and other organizations

Unexpected protein partnership has implications for cancer treatment

Date:
April 15, 2014
Source:
National Institute of Environmental Health Sciences (NIEHS)
Summary:
Two unlikely partners in a type of immune cell called a macrophage that work together in response to cancer drugs have been found by researchers. This partnership increases inflammation in a way that may alter tumor growth.

Scientists have identified two unlikely partners, in a type of immune cell called a macrophage, that work together, in response to cancer drugs, to increase inflammation in a way that may alter tumor growth. Researchers from the National Institutes of Health published the study in the journal Cancer Research.

These partners are the p53 protein that suppresses tumors and the nuclear factor-kappaB (NF-kappaB) protein that stimulates their growth. Blocking this partnership could help prevent inflammation from occurring in cancer patients undergoing chemotherapy.

"Since many chemotherapy drugs target p53 to fight cancer cells, our finding helps us better understand the inflammatory-based side effects often seen in patients undergoing chemotherapy, as well as roles for inflammation within tumors," said Julie Lowe, Ph.D., lead author on the paper and fellow in the Laboratory of Respiratory Biology at the National Institute of Environmental Health Sciences (NIEHS), part of NIH.

Both p53 and NF-kappaB have been studied in modern cancer research. But, until now, they have generally been viewed as having opposite effects on growth. This study is among the first to show a cooperative interaction between p53 and NF-kappaB in human immune cells, and to reveal unexpected roles of p53 in tumor-related macrophages.

The study described a new collaboration between two major pathways to generate inflammation, said Michael Resnick, Ph.D., senior author and head of the NIEHS Chromosome Stability Group.

Inflammatory responses to exposures of p53-activating chemotherapeutic drugs were measured in immune cells from the blood and lungs of healthy volunteers at the NIEHS Clinical Research Unit. The researchers found that these drugs enhanced the expression of molecules that direct inflammation, an effect that required both p53 and NF-kappaB. The study also characterized a role for p53 in immune cells associated with tumors.

Currently, most cancer therapies related to the p53 tumor suppression process are directed at activating the p53 protein. However, this study has clinical applications not only for cancer, but also for smoking-related lung disease. In both cases, p53 is activated in immune cells through chemotherapy, radiation, or smoking. Modifying this pathway through inhibitors of p53 activation could decrease the inflammatory response, both in cancer treatment and in lung diseases, such as chronic obstructive pulmonary disease.


Story Source:

The above story is based on materials provided by National Institute of Environmental Health Sciences (NIEHS). Note: Materials may be edited for content and length.


Journal Reference:

  1. J. M. Lowe, D. Menendez, P. R. Bushel, M. Shatz, E. L. Kirk, M. A. Troester, S. Garantziotis, M. B. Fessler, M. A. Resnick. p53 and NF-B Coregulate Proinflammatory Gene Responses in Human Macrophages. Cancer Research, 2014; 74 (8): 2182 DOI: 10.1158/0008-5472.CAN-13-1070

Cite This Page:

National Institute of Environmental Health Sciences (NIEHS). "Unexpected protein partnership has implications for cancer treatment." ScienceDaily. ScienceDaily, 15 April 2014. <www.sciencedaily.com/releases/2014/04/140415111320.htm>.
National Institute of Environmental Health Sciences (NIEHS). (2014, April 15). Unexpected protein partnership has implications for cancer treatment. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2014/04/140415111320.htm
National Institute of Environmental Health Sciences (NIEHS). "Unexpected protein partnership has implications for cancer treatment." ScienceDaily. www.sciencedaily.com/releases/2014/04/140415111320.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins